Side effects with Eviplera
The summary of product characteristics for Eviplera (emtricitabine, rilpivirine, tenofovir disoproxil; Gilead) now states that Eviplera must be discontinued as soon as serious skin and/or mucosal reactions are observed, and appropriate therapy should be initiated.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200173
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com